In which country was the original drug Osimertinib/Tagressa developed?

Osimertinib is a targeted drug used to treat EGFR mutant non-small cell lung cancer (NSCLC). It is developed and produced by global pharmaceutical company AstraZeneca. AstraZeneca is headquartered in the United Kingdom. As a leading global pharmaceutical company, AstraZeneca is committed to the research and development of innovative drugs, especially in oncology, cardiovascular, diabetes and other fields.

The development of osimertinib provides a more precise treatment option for patients with EGFR mutation-positive non-small cell lung cancer. Unlike traditional first- and second-generation EGFR inhibitors, osimertinib can effectively overcome common EGFR T790M mutation resistance and therefore has significant clinical efficacy. It inhibits the growth and spread of tumor cells by inhibiting the mutant tyrosine kinase activity of EGFR.

Osimertinib is mainly produced by AstraZeneca and is produced and sold in many countries and regions around the world. The production of drugs complies with international standards to ensure the quality and efficacy of drugs. AstraZeneca has production bases in multiple countries, including the United States, Europe and other places, which are responsible for the production, packaging and distribution of drugs.

Although osimertinib is produced by AstraZeneca in the United Kingdom, the drug's production and sales network covers the world, and patients in many countries and regions can obtain this treatment option through formal channels. The approval and launch time of osimertinib vary globally, and the specific launch time and indications will also vary according to the requirements of regulatory agencies in different countries.

In summary, Osimertinib/Tagressa is produced by AstraZeneca. AstraZeneca is headquartered in the United Kingdom, and the production and distribution of the drug involves multiple countries and regions. As an innovative targeted drug, osimertinib provides a new treatment option for patients with EGFR-mutant non-small cell lung cancer, and its global production and sales network ensures wide availability of the drug.

Reference materials:https://go.drugbank.com/drugs/DB09330